A Multi‐Center Clinical Trial to Evaluate the Efficacy of the Next Generation TriHex Technology Antiaging Regimen

TL;DR

A clinical trial tested a new anti-aging serum's effectiveness in improving skin hydration, elasticity, and quality over 12 weeks.

Contribution

The study validates the efficacy and safety of the reformulated TriHex Technology serum with Octapeptide-45 and magnolol.

Findings

Significant improvements in facial skin hydration, elasticity, and quality were observed after 12 weeks.

Histology showed increased new adipocytes, keratinocyte HA, and dermal collagen and elastin fibers.

The serum was well-tolerated and effective across Fitzpatrick skin Types I–VI.

Abstract

Alastin Restorative Skin Complex Serum with TriHex Technology (Alastin Skincare Inc., Carlsbad, CA) has undergone reformulation to add Octapeptide‐45 and magnolol for improving facial skin hydration, elasticity, plumping, and overall skin quality. Detailed science on TriHex Technology 2.0 and magnolol has been recently published. This open‐label study was conducted to validate the science and demonstrate product efficacy and tolerability in individuals with moderate to severe facial skin aging.

A multi‐center clinical study was conducted from February to August 2024. A total of 44 eligible participants (43 female, 1 male), ages 35–69 years, and Fitzpatrick skin Types I–VI were enrolled in and completed the study following 12 weeks of Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology (RSC 2.0) use twice daily, along with an Alastin Skincare Inc. supportive regimen (cleanser, moisturizer, sunscreen used as needed). A 1‐week run‐in phase using the supportive regimen only was conducted, and eligibility was reassessed at baseline. Follow‐up visits were performed at Weeks 4, 8, and 12, where facial skin quality parameters were evaluated clinically and subject assessments and satisfaction questionnaires, biopsy collection, photography, and hydration and elasticity measurements were completed. Participants also maintained a study diary over the 12‐week treatment period.

Significant improvements for all clinically evaluated facial skin parameters were achieved at Week 12. Histology revealed increased stimulation of new adipocytes, epidermal keratinocyte HA (CD44), and new dermal collagen and elastin fibers post treatment.

Alastin Restorative Skin Complex Serum 2.0 with TriHex Technology has been demonstrated to be safe and effective for improving overall facial skin quality, achieving notable improvements in volume, plumping, hydration, and extracellular matrix (ECM) collagen and elastin stimulation.

Figures